Evidence · Nutrition you can read

What we know, and what we don't

What the research shows, and what it doesn't.

Last reviewed 22 Sep 2026
Written by Stephen Smith

There are three kinds of evidence, and they are not the same thing

Evidence about an ingredient. Someone studied a substance and published what happened. This is what exists for most of our ingredients.

Evidence about a formula. Someone studied this exact product, at this exact dose, in people just like you. Almost nobody has that. We don't either — yet.

A brand saying something confidently. Confidence is not evidence, and it is easy to mistake for it.

We'll always tell you which kind we're citing.

What has been published about our ingredients

All of the below was done by other people, on ingredients, not on Oratide products. Every one is cited in full so you can read it yourself — and read what it doesn't say. Each card carries the date we last checked the citation against the publisher, and what we checked it against. Where we went looking and found less than we expected, we've said that too.

Protein, and why we say 20 grams

Protein quality is scored by a method called PDCAAS, which corrects the raw gram figure for how well the body can actually use the amino acids. Whey scores 1.0 — the top of the scale. That is why Daily's panel prints 40% of the protein Daily Value without a correction, and why the same 10 grams of collagen in Restore prints no percentage at all.

That is nutrition arithmetic, not a research finding, and we are not going to dress it up as one. We are also not going to point you at somebody's satiety study: Daily doesn't claim to make you feel full any more. It used to, when it contained a viscous fiber. We took the fiber out, and the claim came out with it.

Vitamin D, zinc and vitamin B12 when intake drops

Three 2026 reviews looking at hair loss during rapid weight loss reach the same conclusion about mechanism: the shedding tracks the speed and size of the weight loss rather than being a direct effect of any medication, and it travels with nutritional shortfall. The first states that this population is associated with "micronutrient deficiencies including vitamin D, iron deficiency, and insufficient dietary calcium and protein," and recommends ensuring adequate intake of protein, iron, zinc, vitamin D, B12 and A.

Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2). doi:10.1177/00368504261444578

Design
Systematic review
Participants
Not applicable — a review of published evidence, not a trial
Duration
Not applicable

What it foundNames what runs short during rapid weight loss: "micronutrient deficiencies including vitamin D, iron deficiency, and insufficient dietary calcium and protein." Recommends that clinicians counsel on adequate intake of protein, iron, zinc, vitamin D, B12 and A.

What it does not supportThat supplying any of those nutrients changes what happens to anyone's hair. It reviews evidence and makes a counselling recommendation. It reports no trial that tested supplementation, and it did not study a product — ours or anyone's.

Verified 16 September 2026

Read the paper
How it was checked

CrossRef exact match on all four authors in order, title, journal, volume 109, issue 2, article number, year, SAGE Publications, ISSN 0036-8504 / 2047-7163. The quoted line and the counselling recommendation were confirmed in the paper. Free full text located at PMC13100445 and added to the citation.

The second is shorter — three pages — and lands in the same place on mechanism.

Branyiczky MK, Lowe MS, McMullen E, Donovan J, Khosravi-Hafshejani T. Effects of GLP-1 receptor agonists on hair loss and regrowth: a systematic review. International Journal of Dermatology. 2026;65(5):1030–1032. doi:10.1111/ijd.70133

Design
Systematic review — concise, three pages
Participants
Not applicable — a review of published evidence
Duration
Not applicable

What it foundReaches the same conclusion on mechanism as Gupta: the shedding tracks the speed and size of the weight loss rather than being a direct effect of any medication, and it travels with nutritional shortfall.

What it does not supportThat supplementing changes an outcome. At three pages this is a concise review rather than an extended one — Gupta carries more of the load, which is why Gupta is cited first.

Verified 16 September 2026

How it was checked

CrossRef confirms all five authors, the title, the journal, volume 65, issue 5, pages 1030–1032, Wiley, ISSN 0011-9059 / 1365-4632. Online first 31 October 2025, in print 2026.

The third pools the cohort data, and puts the same conclusion more bluntly: the risk is "primarily mediated by weight loss-induced micronutrient deficiency." Not the medicine. The eating less.

Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disorders. 2026. doi:10.1159/000553070 PMID 42621629

Design
Systematic review and meta-analysis
Participants
17 studies pooled, 1,091,743 patient-exposures
Duration
Not applicable

What it foundThe authors' conclusion, verbatim: "GLP-1 RAs are associated with a significant 40% increased risk of non-scarring alopecia, driven by telogen effluvium and androgenetic alopecia and primarily mediated by weight loss-induced micronutrient deficiency."

What it does not supportThat closing a micronutrient gap changes any hair outcome. It identifies a mechanism; it tested no intervention and no product. It is also evidence about a class of medicines, not about Oratide — nothing in it may be used to imply that our products treat, prevent or reverse anything.

Verified 20 September 2026

How it was checked

Resolved via DOI to Karger and cross-checked in PubMed, PMID 42621629. All three authors, the title and the journal confirmed. The quoted conclusion was read verbatim from the abstract. No volume, issue or page range is assigned — it is online ahead of print, which is why none is printed above.

That is a statement about nutrition, not about our product. We put vitamin D, zinc and B12 in Daily because these reviews name them. We have not tested whether supplying them changes anything for anyone, and none of them looked at a product like ours.

Here is the part that decides whether any of this is evidence about you. Every one of these reviews recommends making sure intake is adequate. Not one of them is reporting a study that tested whether supplementing actually changes what happens to anyone's hair. Nobody has run that trial — not for protein, not for vitamin D, zinc or B12, not in this population. Including us.

What we know is that a nutritional gap opens when intake drops sharply, and that doctors are being told to close it. What nobody knows is whether closing it with a scoop of powder changes an outcome. We would rather you bought this, understanding that distinction, than not understanding it.

L-cystine with botanicals — the closest published work, and how far away it is

A six-month double-blind placebo-controlled trial in 80 people reported hair density up 9.9 hairs per cm² at three months and 12.3 at six, against placebo. It is the nearest thing in the literature to a formula like Roots, so here is the distance between them, measured.

Ten ingredients to our four. That supplement contained L-cystine, Serenoa repens, pumpkin seed oil, Pygeum africanum, zinc, nicotinamide, vitamin B6, pantothenic acid, biotin and Equisetum arvense. We share four, and one of those is a different preparation — we use milled pumpkin seed where they used the oil. The paper publishes no doses at all, only a list of names, so nobody can honestly say their formula matches it. And 60 of the 80 participants had androgenetic alopecia and 20 had diagnosed chronic telogen effluvium: patients at a clinic, not people browsing a website.

So that result is not evidence about Roots, and we are not going to borrow it. What Roots actually rests on is simpler and better established: hair is largely keratin, keratin is largely built from cystine, and copper, biotin and pantothenic acid are essential nutrients with Daily Values set by regulation. That is a nutritional argument, and it holds without anyone's trial.

Piquero-Casals J, Saceda-Corralo D, Aladren S, Bustos J, Fernández-Botello A, Navasa A, Logusso G, Jourdan E, Mir-Bonafé JF, Morgado-Carrasco D. Oral supplementation with l-cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in chronic telogen effluvium and androgenetic alopecia: a double-blind, placebo-controlled, randomized clinical study. Skin Appendage Disorders. 2025;11(1):27–35. doi:10.1159/000540081 PMID 39911983

Design
Double-blind, placebo-controlled randomised clinical trial
Participants
80 clinic patients — 60 with androgenetic alopecia, 10 of them women, and 20 women with chronic telogen effluvium
Duration
6 months

What it found"Hair density increased by 9.9 hairs/cm2 after 3 months and 12.3 hairs/cm2 after 6 months … statistically significant when compared to placebo."

What it does not supportRoots. Ten ingredients against our four, and one of those four is a different preparation — we use milled pumpkin seed, the trial used pumpkin seed oil. The paper publishes no doses at all, only a list of names, so nobody can honestly claim to match its formula. And the participants were diagnosed patients at a clinic, not people browsing a website.

Verified 16 September 2026

How it was checked

Triple-confirmed. DOI resolves to Karger at volume 11, issue 1, page 27; PubMed holds it as PMID 39911983 with all ten authors and pages 27–35; additionally indexed in Cochrane CENTRAL as CN-02806486, which only accepts controlled trials. Every substantive claim was checked against the publisher's full text rather than the abstract: Table 1 lists ingredient names with no quantities anywhere, "Pumpkin seed oil (Cucurbita pepo)" appears verbatim, and both the population split and both density figures are confirmed.

Biotin — the evidence is weak, which is why we say nothing about it

Roots contains 300 mcg of biotin, and we make no claim for it anywhere. This is the reasoning.

The paper most often reached for is a 2017 review of case reports. It found eighteen reported cases of biotin used for hair and nails — and in every one of them the patient had an underlying pathology: an inherited metabolic cause, a proven deficiency, or a similar identifiable reason. The authors note the lack of sufficient evidence for supplementation in healthy people.

Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disorders. 2017;3(3):166–169. doi:10.1159/000462981

Design
Review of published case reports
Participants
18 reported cases of biotin use for hair and nail changes
Duration
Not applicable

What it foundThe authors found 18 reported cases of biotin use for hair and nail changes. In every one of them the patient had an underlying pathology for poor hair or nail growth — an inherited metabolic cause, a proven deficiency, or a similar identifiable reason. The authors note the lack of sufficient evidence for supplementation in healthy individuals.

What it does not supportAny benefit from biotin for a person who is not deficient. This is the paper most often invoked as evidence that biotin helps hair; read properly it says close to the opposite. It does not support Roots, and Roots makes no biotin claim.

Verified 20 September 2026

How it was checked

Citation and abstract read at the publisher, Karger, Skin Appendage Disorders 3(3):166–169, doi 10.1159/000462981. The case count, the statement that every one of those cases had an underlying pathology, and the conclusion on healthy individuals all come from the abstract.

A 2026 systematic review across ten studies reaches the same place, and says it without hedging.

Moltó-Balado P, Simeó-Monzo A, del Barrio-Gonzalez A. Effectiveness of biotin supplementation for hair growth in patients with alopecia: a systematic review. Dermato. 2026;6(2):17. doi:10.3390/dermato6020017

Design
Systematic review
Participants
10 studies across mixed populations — telogen effluvium, androgenetic alopecia, alopecia areata in children, healthy men, patients on isotretinoin
Duration
Six weeks upwards; doses 1.25–10 mg/day orally, 5 mg intramuscularly, and topical preparations

What it foundThe authors' conclusion, verbatim: "Current evidence does not support routine biotin supplementation for alopecia in the absence of documented deficiency, although it may be considered in scenarios with risk or confirmation of deficiency/malabsorption."

What it does not supportBiotin for hair in anyone without a documented deficiency — which is almost everyone who buys a hair supplement. Note the doses reviewed were 1.25 to 10 mg a day. Roots contains 300 mcg, an order of magnitude below the low end, so this review is not even testing our amount. It is the reason Roots makes no biotin claim.

Verified 20 September 2026

Read the paper
How it was checked

Read at the publisher, MDPI, Dermato 2026;6(2):17, doi 10.3390/dermato6020017. Author list, study count, populations, dose range and the quoted conclusion taken from the article page. Open access.

And the doses those reviews examined were 1.25 to 10 mg a day. Roots contains 0.3 mg — less than a quarter of the smallest amount anyone studied. So the negative evidence is not measuring our amount. That is not a defence of biotin, and we are not offering it as one; it is the reason we neither claim it works nor pretend the question is closed.

One thing about biotin is well established, and it has nothing to do with hair: it interferes with a range of laboratory blood tests that use the biotin–streptavidin binding system. That is why the Roots label carries a lab-test warning — it was on the pack before this page discussed it.

U.S. Food and Drug Administration. The FDA warns that biotin may interfere with lab tests. FDA safety communication. 2017.

Design
Regulatory safety communication — not a study
Participants
Not applicable
Duration
Issued November 2017; FDA has continued to publish on the subject, including a page on troponin assays dated June 2022

What it foundBiotin can significantly interfere with immunoassay-based laboratory tests, which use the biotin–streptavidin binding system, and can cause incorrect results that go undetected. Cardiac troponin is the assay FDA has pressed hardest on: it names specific troponin devices that have not addressed the risk, and states it "has continued to receive adverse events reports indicating biotin interference caused falsely low troponin results."

What it does not supportIt is not evidence that biotin does anything for hair. It is a safety fact, and it is the reason the Roots label carries a lab-test warning.

Two limits are worth stating plainly. A death was reported to FDA following a possibly falsely low troponin result, but biotin interference was never confirmed and the troponin was measured after death — so it is a report FDA received, not a death caused by biotin. And the specific dose thresholds that circulate in clinical guidance do not come from FDA, so we do not attach one to FDA's name.

Verified 20 September 2026

Read the paper
How it was checked

Read directly at FDA's own in-vitro diagnostics page on biotin interference with troponin assays; the quoted line and the June 2022 date come from it. The November 2017 origin date, and the detail of the unconfirmed death, come from UC Davis Health clinical laboratory guidance, which quotes FDA.

The dose thresholds in circulation — no risk at multivitamin levels of 30–60 mcg, minimal risk below 2,500 mcg a day, potential interference above 5,000 — come from that same laboratory guidance rather than from FDA, so we do not attribute any threshold to FDA. FDA's 2019 update page did not resolve when we went looking for it, and we have not read it.

Collagen peptides

A 2026 meta-analysis pooled 35 randomized controlled trials and 2,534 participants taking 500 mg to 10 g of collagen peptides a day for four to sixteen weeks. It found a modest improvement in skin hydration and in skin elasticity — standardized mean differences of 0.44 and 0.62 respectively, both statistically significant.

If you are buying collagen for wrinkles, buy something else. The same review reports "a complete lack of therapeutic efficacy across all time points" on wrinkle depth — an apparent effect at week eight turned out to be driven entirely by one extreme outlying study, and once that was removed the result was, in the authors' words, "statistically indistinguishable from placebo." Dermal density showed no significant benefit either.

We are telling you that because it is the thing most people assume collagen does, and because we would rather lose the sale than have you find out in twelve weeks. Skin hydration and elasticity are what the evidence supports, so those are the only two things Restore claims. Not hair. Not nails. Not connective tissue — we had those on the page and took them off when we read the review properly, because it covers skin and nothing else.

Our 10 g is at the top of the range those trials used. That is why it is 10 g.

Batool A, Abbas MS, Farooq R, Akbar MA, Ahmed A, Kanwal W, Ali H, Ahmad A, Junaid M, Hanif MS, Nunes Junior EBD, Aminpoor H. Oral collagen peptides and skin rejuvenation: a systematic review and an updated meta-analysis of randomized controlled trials. Journal of Cosmetic Dermatology. 2026;25(7):e71041. doi:10.1111/jocd.71041

Design
Systematic review and meta-analysis of randomised controlled trials
Participants
35 randomised controlled trials, 2,534 participants
Duration
4 to 16 weeks, at 500 mg to 10 g of collagen peptides a day

What it foundModest improvement in skin hydration, SMD 0.44 (95% CI 0.15–0.73), and in skin elasticity, SMD 0.62 (95% CI 0.15–1.10). Both statistically significant.

What it does not supportHair. Nails. Wrinkles. Dermal density. The review is explicit on the last two: on wrinkles the intervention was "statistically indistinguishable from placebo" once a single extreme outlier was removed, and on dermal density "the data do not support a significant therapeutic benefit." Skin hydration and elasticity are what it supports, so those are the only two things Restore claims.

Verified 16 September 2026

Read the paper
How it was checked

CrossRef confirms twelve authors, the title, the journal, volume 25, issue 7, article e71041, 2026, Wiley, ISSN 1473-2130 / 1473-2165. The pooled figures, the wrinkle result and the dermal-density result were all taken from the open-access full text rather than from the abstract, and the full author list was completed from that text on 20 September.

Copper tripeptide-1 — where we found the least

This is the one we expected to be able to support and could not, so here is exactly what happened when we looked.

Searching the published human literature for this peptide and hair returns very little. The only indexed randomized controlled trial we could find was not a study of copper tripeptide-1. It tested a combination of 5-aminolevulinic acid and a copper-free version of the peptide, as a topical spray, in 45 men with diagnosed male pattern hair loss over six months. The peptide was never tested on its own. It reported increases in hair count.

Lee WJ, Sim HB, Jang YH, Lee S-J, Kim DW, Yim S-H. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Annals of Dermatology. 2016;28(4):438–443. doi:10.5021/ad.2016.28.4.438

Design
Randomised controlled trial of a topical spray
Participants
45 men with diagnosed male pattern hair loss
Duration
6 months

What it foundReported increases in hair count.

What it does not supportOratide Scalp. It tested 5-aminolevulinic acid combined with a copper-free version of the peptide — a different molecule from copper tripeptide-1 — and the peptide was never tested on its own. Diagnosed male population, topical spray, and a hair-growth endpoint that a cosmetic may not claim in any case. This is the one we expected to be able to support and could not.

Verified 16 September 2026

How it was checked

Registry match on all six authors, title, journal, volume 28, issue 4, pages 438–443, 2016. A PubMed search for GHK-Cu and hair returns seven results, of which six are laboratory, mechanistic or review papers; this is the only human randomised controlled trial among them. The two studies commonly cited in this category — a 2015 trial in postmenopausal women and a 2018 comparison against minoxidil — could not be verified in the medical literature index and are therefore not cited.

Two other studies get cited constantly in this category — a 2015 trial in postmenopausal women and a 2018 comparison against minoxidil. We went looking for both and could not verify either in the medical literature index. They may exist somewhere we did not reach. We are not going to cite a paper we could not find.

So: copper peptides have been used in cosmetics for decades, which is a real fact about safety and history and not a fact about results. That is the entire basis for our serum, and it is why the Scalp page promises less than any other page on this site. It is a cosmetic. It is allowed to talk about how hair looks, and we do not have evidence that would let us say more than that even if the law allowed it.

What we have not proven

We have not run a clinical trial on any Oratide product. Not one.

Which means:

  • We can't tell you whether you'll lose weight, or how much, because we haven't measured it
  • We can't tell you whether your hair will change, or by how much, because we haven't measured it
  • We can't tell you our products work better than anyone else's, because we haven't compared them
  • We can't tell you ours absorbs better, because the published data doesn't support that for anyone

The only thing that would change any of those sentences is a trial. Until we have run one, they stand.

What didn't work

This section is empty, because we haven't finished a study yet. When we have, anything that failed goes here in the same detail as anything that succeeded — the endpoints that didn't move, the things we hoped for and didn't get.

We're telling you this now, while the section is empty, so you can hold us to it later.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.